Merck’s Zilovertamab Vedotin Achieves 100% Complete Response in Phase 2 DLBCL Trial, Setting Stage for Phase 3

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the first presentation of data from the Phase 2 waveLINE-007 trial evalu...

December 09, 2024 | Monday | News
Kite Presents Groundbreaking Real-World Data at ASH, Showcasing Yescarta®'s Impact on Relapsed/Refractory Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced findings from three new analyses for Yescarta ® (axicabtagene ciloleucel) that demonstrate i...

December 09, 2024 | Monday | News
Genentech Presents Positive Five-Year Follow-Up Data from POLARIX Study on Polivy® Combination for Untreated DLBCL

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced data from a five-year follow-up of the pivotal Phase III POLARIX study evalu...

December 09, 2024 | Monday | News
Agios Pharmaceuticals Announces Positive Phase 3 ENERGIZE-T Study Results for Mitapivat in Transfusion-Dependent Thalassemia

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...

December 09, 2024 | Monday | News
AstraZeneca’s Imfinzi Gains FDA Approval for Limited-Stage Small Cell Lung Cancer, Offering New Hope for Patients

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cance...

December 09, 2024 | Monday | News
Zepbound® (Tirzepatide) Outperforms Wegovy® (Semaglutide) in Phase 3b SURMOUNT-5 Trial, Demonstrating Superior Weight Loss

Eli Lilly and Company (NYSE: LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® ...

December 09, 2024 | Monday | News
FDA Accepts Roche's Supplemental Biologics License Application for Columvi® in Combination with GemOx for Relapsed or Refractory DLBCL

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics Licen...

December 09, 2024 | Monday | News
OmniScience and INmune Bio Join Forces to Transform Global Alzheimer’s Trial Operations with GenAI-Powered Data Platform

OmniScience and INmune Bio announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer&...

December 05, 2024 | Thursday | News
Nxera Pharma Launches Phase 3 Trial of QUVIVIQ™ (Daridorexant) in South Korea to Address Insomnia Epidemic

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorex...

December 05, 2024 | Thursday | News
Duality Biologics Signs Exclusive Option Agreement with GSK for ADC Candidate DB-1324 in Gastrointestinal Cancer

 Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjuga...

December 04, 2024 | Wednesday | News
Beyond Cancer Receives Israeli Ministry of Health Approval for Phase 1b Trial of LV UNO in Combination with Anti-PD-1 Therapy

Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors...

December 04, 2024 | Wednesday | News
Amarna Therapeutics Forms Strategic Partnership with NorthX Biologics to Advance Gene Therapy Development

Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company specializing in transformative gene therap...

December 04, 2024 | Wednesday | News
Merck’s Sacituzumab Tirumotecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug...

December 04, 2024 | Wednesday | News
Polyrizon Signs Manufacturing Agreement with Eurofins CDMO for PL-14 Allergy Blocker Clinical Trial

Polyrizon Ltd. (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, anno...

December 03, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close